HomeAI · summaries
Storia in 2 fonti
AbbVie lines up Qulipta expansion with phase 3 win in untapped menstrual migraine indication
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative Qulipta, also known as atogepant. | With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative Qulipta, also known as atogepant.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
AbbVie lines up Qulipta expansion with phase 3 win in untapped menstrual migraine indication
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative Qulipta, also known as atogepant. | With positive phase 3…
- ·
benzinga.com
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days - AbbVie (NYSE:ABBV)
AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety in preventing menstrual migraines.